{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hematopoietic+stem+cell+infusion&page=19",
    "query": {
      "intervention": "hematopoietic stem cell infusion",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 2925,
    "total_pages": 293,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hematopoietic+stem+cell+infusion&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hematopoietic+stem+cell+infusion&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T18:54:39.615Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02039726",
      "title": "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AML"
      ],
      "interventions": [
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Salvage Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2014-05",
      "completion_date": "2020-09-08",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 36,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 31 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039726"
    },
    {
      "nct_id": "NCT03133221",
      "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Follicular Lymphoma",
        "Indolent Lymphoma",
        "B-cell Lymphoma",
        "Transformed Lymphoma",
        "Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia",
        "Small Lymphocytic Lymphoma",
        "Lymphoplasmacytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zydelig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-10-23",
      "completion_date": "2024-09-29",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03133221"
    },
    {
      "nct_id": "NCT05873205",
      "title": "Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blood Cancer",
        "Refractory Immune Cytopenias"
      ],
      "interventions": [
        {
          "name": "Isatuximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2023-07-21",
      "completion_date": "2027-06-29",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05873205"
    },
    {
      "nct_id": "NCT02137096",
      "title": "Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Nasopharynx Carcinoma"
      ],
      "interventions": [
        {
          "name": "Etoposide phosphate",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Autologous Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 1,
      "start_date": "2014-06",
      "completion_date": "2017-05-09",
      "has_results": true,
      "last_update_posted_date": "2019-06-24",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02137096"
    },
    {
      "nct_id": "NCT04083170",
      "title": "Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Erythroid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Megakaryoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "HIV Infection",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Non-Hodgkin Lymphoma",
        "Refractory Anemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Dilanubicel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "6 Months to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-10-06",
      "completion_date": "2022-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083170"
    },
    {
      "nct_id": "NCT00582894",
      "title": "Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematological Neoplasms",
        "Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Busulfex, Fludarabine, ALemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-02",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2011-04-22",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582894"
    },
    {
      "nct_id": "NCT01929980",
      "title": "Bortezomib to Treat Significant Complication of HSCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplantation",
        "Refractory Autoimmune Cytopenia(s)"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "4 Months to 29 Years"
      },
      "enrollment_count": 4,
      "start_date": "2012-07",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-10-24",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929980"
    },
    {
      "nct_id": "NCT00029380",
      "title": "Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Anemia, Sickle Cell",
        "Beta-Thalassemia",
        "Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Sangstat",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "3 Years to 14 Years"
      },
      "enrollment_count": 30,
      "start_date": "1999-01",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-29",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 14,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00029380"
    },
    {
      "nct_id": "NCT03940586",
      "title": "Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus (CMV) Infection"
      ],
      "interventions": [
        {
          "name": "Letermovir oral granules",
          "type": "DRUG"
        },
        {
          "name": "Letermovir tablet",
          "type": "DRUG"
        },
        {
          "name": "Letermovir intravenous",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 65,
      "start_date": "2019-08-08",
      "completion_date": "2023-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Orange, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03940586"
    },
    {
      "nct_id": "NCT03970096",
      "title": "Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic CD34+-enriched and CD45RA-depleted PBSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration and Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "1 Year to 60 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-11-19",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-15T18:54:39.615Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Pittsburgh, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970096"
    }
  ]
}